Developer docs
API playgroundTry for free, no card

Search company profiles

KCNT1 Epilepsy Foundation

Full company profile

uuid003jrj1

Namestring
KCNT1 Epilepsy Foundation
Legal namestring
KCNT1 Slack Epilepsy Foundation
Company typeenum
Private
Founded yearint
2019
Descriptiontext

The KCNT1 Epilepsy Foundation is a U.S. 501(c)(3) nonprofit founded in 2019 by Seth Greenblott, along with co-founders Justin West, MD and Samantha MacMechan, to serve families affected by KCNT1-related epilepsy — an ultra-rare genetic disorder with fewer than 20 cases per million people, causing severe and often intractable seizures, severe developmental delay, and elevated mortality risk including SUDEP. The foundation is headquartered (mailing address) in Scottsdale, Arizona, operates with an all-volunteer Board of Directors and 1-10 employees, and serves a global community spanning the United States, Canada, the United Kingdom, Portugal, Germany, and Australia. There are no FDA-approved disease-modifying therapies for KCNT1-related epilepsy.

The foundation's core products are organized around three pillars: family support, research acceleration, and clinical trial readiness. Research infrastructure includes the KCNT1 International Registry (100+ enrolled patients with documented variants), a Digital Natural History Study conducted with Invitae/Ciitizen (50+ U.S. patients contributing medical records and genetic reports), and a biobank with biospecimen collection and hiPSC development through COMBINEDBrain and Van Andel Institute (since 2023). Family-facing products include the Family Contact List, Parent Ambassador Program, an annual Family and Professional Conference, multilingual educational resources (Portuguese, French, German, Spanish), and FDA Patient Listening Sessions (held April 22, 2024). Research funding is delivered through seed grants, the Penn Orphan Disease Center Million Dollar Bike Ride (raising ~$38K in 2024 and ~$39K in 2023, each unlocking ~$30K in matching), and a co-funded $100,000 Rare Epilepsy Partnership Award with CURE Epilepsy.

The foundation operates as a patient-driven, community-led organization. Revenue is generated entirely from charitable donations, fundraising events (golf tournaments, MDBR, Facebook/GoFundMe), corporate matching, eBay affiliate sales, conference sponsorships from biotech/pharma, and grants — most notably the multi-year Chan Zuckerberg Initiative Rare As One Network grant awarded in October 2024. GTM is community-led: families are reached via the website, email newsletters, Facebook (including private support groups), in-person conferences, and earned media (LA Times, Fox 32, ABC, ITV). Strategic partners span biotech (Actio Biosciences, Atalanta Therapeutics, Biogen, Praxis/UCB), academic researchers (UCL, UC Davis, CHOP), and rare disease infrastructure (NORD, CZI, COMBINEDBrain, Van Andel Institute, Penn ODC, CURE Epilepsy).

Short descriptiontext

The KCNT1 Epilepsy Foundation is a Scottsdale-based 501(c)(3) nonprofit founded in 2019 that operates a patient registry, biobank, and digital natural history study to accelerate research and clinical trial readiness for the ultra-rare KCNT1-related epilepsy community worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersScottsdale, United States
HQ citystring
Scottsdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Rare disease advocacy, Epilepsy research foundation, Patient registry services, Family support services, Clinical trial readiness
Industry4 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAKAIAB
Epilepsy & Seizure Disorders
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAIAO
Neurogenetics & Rare Neurologic Diseases
NAICS code1 code
  • Voluntary Health Organizations813212
SIC code1 code
  • Services-Social Services8300
Product category
Rare Disease Patient Advocacy & Epilepsy Research Foundation
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Charitable Donations
TypeOthers
Description

Individual donations from supporters via PayPal Giving Fund, credit card, check, Donor Advised Funds, IRA Required Minimum Distributions (RMDs/ QCDs), corporate matching, and eBay sales through affiliate programs.

kcnt1epilepsy.org
2Fundraising Events
TypeOthers
Description

Revenue from events including Million Dollar Bike Ride, golf tournaments, Facebook fundraisers, and GoFundMe campaigns.

kcnt1epilepsy.org
3Conference Sponsorships
TypeOthers
Description

Sponsorship revenue from pharmaceutical companies and industry partners for family and professional conferences.

kcnt1epilepsy.org
4Mission-Aligned Financial Arrangements
TypeLicensing Royalties
Description

The foundation may participate in revenue sharing, cost recovery, licensing, or other financial-return provisions through biobank partnerships, data partnerships, research collaborations, or potential spinout-related agreements.

kcnt1epilepsy.org
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

The KCNT1 Epilepsy Foundation is a 501(c)(3) nonprofit that supports families affected by KCNT1-related epilepsies and accelerates research toward disease-modifying treatments. It operates a KCNT1 International Registry (>100 patients), a U.S. Digital Natural History Study with Ciitizen (>50 patients), a biobank with iPSC biospecimens through COMBINEDBrain/Van Andel Institute, a Family Contact Network connecting parents globally, a Research Funding Program issuing seed and Million Dollar Bike Ride grants, and FDA Patient Listening Sessions representing community needs to regulators.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over 100 persons with KCNT1 variants enrolled in registry
+4 more records
Product overview1 text field

The KCNT1 Epilepsy Foundation offers a comprehensive suite of patient-centered services organized around three pillars: family support, research acceleration, and community building. The core offerings include a Family Contact List and Network connecting affected families worldwide; a KCNT1 Registry and Biobank (in partnership with COMBINEDBrain and Van Andel Institute) collecting patient data and biospecimens; a Digital Natural History Study with Ciitizen; a Clinical Trial Hub preparing families for trial participation; and a Research Funding Program providing seed grants and partnering on research initiatives. The Foundation also organizes Family and Professional Conferences, facilitates FDA Patient Listening Sessions, and operates a Donation Platform with multiple giving mechanisms. All services work together to accelerate discovery of disease-modifying treatments for KCNT1-related epilepsy.

Product and service9 records
1Family Contact List / Family Network
CategoryFamily Support Service
Description

A contact registry connecting families affected by KCNT1-related epilepsy. Parents and caregivers can register via online forms (available in English, Portuguese, French, German, and Spanish) to receive updates about educational events, research opportunities, and clinical trials, and to connect with other KCNT1 families globally.

2KCNT1 International Registry and Biobank
CategoryResearch Infrastructure
Description

A detailed, secure, and re-contactable patient database with known KCNT1 mutation variants (over 100 persons enrolled) and a biobank collecting biospecimens for iPSC development and trio genome testing, operated in partnership with COMBINEDBrain and Van Andel Institute, with brain tissue from two donors available through NIH Neurobank.

3Digital Natural History Study
CategoryResearch Infrastructure
Description

A U.S. digital natural history study operated in partnership with Ciitizen (Invitae) that uses patient medical records and genetic reports to characterize KCNT1-related epilepsy progression and accelerate rare disease drug development, covering more than 50 patients.

4Clinical Trial Hub
CategoryClinical Trial Readiness Service
Description

Information and resources about ongoing and upcoming clinical trials for KCNT1-related epilepsy, helping families understand trial opportunities, navigate informed consent (including ASO therapy education), and prepare for participation.

5Research Funding Program
CategoryResearch Grant Funding
Description

Seed grants, targeted research priorities, and partnership programs funding high-impact KCNT1 research to accelerate therapeutic development, including Million Dollar Bike Ride grants (with Penn ODC matching up to $30,000) and co-funding partnerships with organizations such as CURE Epilepsy (e.g., $100,000 Rare Epilepsy Partnership Award).

6Research Library
CategoryResearch Resource
Description

A Zotero-hosted library containing scientific publications related to KCNT1/Slack Ion Channelopathy and epilepsy research, providing access to academic literature for researchers and clinicians.

7Family and Professional Conferences
CategoryCommunity Event
Description

Annual in-person and virtual conferences connecting KCNT1 families, clinicians, researchers, and industry partners, featuring educational presentations, clinical trial readiness guidance, networking opportunities, scientific updates, and ASO education sessions.

8Parent Ambassador Program
CategoryCommunity Outreach Program
Description

A network of parent ambassadors who connect affected families and spread awareness of KCNT1-related epilepsy in their regions and countries (e.g., Canada, UK, Portugal), supporting community building and education efforts.

9FDA Patient Listening Sessions
CategoryRegulatory Advocacy Service
Description

Facilitated sessions where KCNT1 patients, caregivers, and advocates share their experiences with the U.S. Food and Drug Administration to emphasize the urgent need for effective treatments, communicate caregiver perspectives on meaningful treatment outcomes and risk tolerance, and inform regulatory processes.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-30
Description

Partnership for educational session on ASO therapies and informed consent process for clinical research, featuring Dr. Olivia Kim-McManus and parent panel.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-15
Description

Launch of Global KCNT1 Registry in partnership with NORD, expanding the foundation's patient registry capabilities internationally.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-18
Description

Foundation co-founder Dr. Justin West engaged with Actio, whose KCNT1 program ABS-1230 is advancing into preclinical testing. Actio developing oral first-in-class small molecule inhibitor for KCNT1-related epilepsy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-31
Description

Atalanta's ATL-201 announced as promising treatment using divalent small interfering RNA (siRNA) technology. Suppressed seizures in genetic mouse model. Advancing toward IND submission and Phase 1 clinical trial.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-07
Description

Conference collaboration hosting first in-person meeting with 14 families from multiple countries. CHOP provided optional clinic appointments and professional presentations on clinical trial readiness.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-20
Description

Co-funding partnership for a $100,000 Rare Epilepsy Partnership Award, co-funding research grants to accelerate KCNT1 research priorities and double the foundation's research reach.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

2024 MDBR grant for characterizing seizures in new KCNT1 G288S mouse model to understand disease mechanisms and support preclinical testing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

2024 Seed Grant using electronic medical records and computational tools to analyze symptoms, medications, and genetic factors to inform clinical trial design.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

2024 co-funded grant with CURE Epilepsy for patient-derived iPSC neuronal models to study KCNT1 function and enable therapeutic screening.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

2024 Research Grant for high-throughput functional testing of KCNT1 variants to understand mutation-specific effects and evaluate therapeutic approaches.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Biobank partnership for biospecimen collection beginning in 2023, with development of induced pluripotent stem cells (hiPSCs) for research purposes.

12Van Andel Institute
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Partnership for biospecimen collection as part of the COMBINEDBrain biorepository initiative, supporting the foundation's biobank development.

kcnt1epilepsy.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

MDBR grant awarded for RNA editing treatment project. Collaboration with Dr. Karda, Dr. Chilcott, Dr. Keegan, Dr. Antonio, Dr. McTague, and Dr. Lignani on pioneering gene therapy research.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-12-13
Description

Strategic collaboration between UCB and Praxis based on Praxis' PRAX-020 program for discovery of small molecule therapeutics for KCNT1 related epilepsies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-08-01
Description

Biogen announced KCNT1 ASO (antisense oligonucleotide) development. Dr. Viet Nguyen presented at foundation research roundtables on gene-based therapy pipeline.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-02-25
Description

Partnership to launch a digital natural history study using Ciitizen's technology platform. The study collects and analyzes patient medical records and genetic reports for over 50 U.S. patients to accelerate rare disease drug development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Brain tissue from two donors available through NIH Neurobank for KCNT1 research.

18Penn Orphan Disease Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Annual Million Dollar Bike Ride partnership. The ODC matches funds raised (up to $30,000) and distributes grants to researchers worldwide with no overhead. Raised nearly $38,000 in 2024 unlocking $30,000 match.

kcnt1epilepsy.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established nonprofit funding epilepsy research broadly, with co-funding partnership with KCNT1 Epilepsy Foundation on the $100K Rare Epilepsy Partnership Award. Highly comparable as a patient-driven funder in the epilepsy research space.

TypeDirect peer
Description

Family-driven 501(c)(3) for ultra-rare genetic neurological disorder with patient registry, natural history study, research funding, and active biotech partnerships. Same playbook as KCNT1 Foundation.

TypeDirect peer
Description

Parent-founded 501(c)(3) for ultra-rare genetic encephalopathy with registry, biobank, family conferences, research grants, and gene therapy partnerships. Near-identical operating model and scale to KCNT1 Foundation.

TypeDirect peer
Description

Umbrella rare disease nonprofit that hosts patient registries and partners with disease-specific foundations; KCNT1 Epilepsy Foundation is actively partnering with NORD to launch its global registry. Directly comparable in registry infrastructure and grantmaking.

TypeDirect peer
Description

Nonprofit consortium advancing therapies for ultra-rare neurodevelopmental disorders, partnered with KCNT1 Foundation for biobank/biorepository since 2023. Directly comparable patient-data and biospecimen infrastructure model.

TypeDirect peer
Description

Disease-specific nonprofit for another severe genetic epilepsy with similar mission structure: patient registry, research grants, family conferences, biotech partnerships, and FDA engagement. Closest analog in scale and operating model.

TypeBroad incumbent
Description

Largest US epilepsy patient advocacy organization with broad research funding, family support, and FDA engagement programs. Comparable operating model but at much greater scale across all epilepsies, not just KCNT1.

TypeDirect peer
Description

Family-led nonprofit for SCN8A-related epilepsy, another ion channelopathy with analogous patient registry, family support, and biotech partnership approach to KCNT1.

9Child Neurology Foundation
TypeBroad incumbent
Description

Broader patient/professional organization supporting families affected by pediatric neurologic conditions including rare genetic epilepsies. Comparable in family support and clinician engagement mission.

10PCDH19 Alliance
TypeDirect peer
Description

Small parent-founded nonprofit supporting research and families affected by PCDH19-related epilepsy, a similarly ultra-rare genetic seizure disorder. Comparable scale, mission, and community-led model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KCNT1 Epilepsy Foundation

Rare Disease Patient Advocacy & Epilepsy Research Foundationkcnt1epilepsy.org

The KCNT1 Epilepsy Foundation is a Scottsdale-based 501(c)(3) nonprofit founded in 2019 that operates a patient registry, biobank, and digital natural history study to accelerate research and clinical trial readiness for the ultra-rare KCNT1-related epilepsy community worldwide.

What KCNT1 Epilepsy Foundation does

The KCNT1 Epilepsy Foundation is a U.S. 501(c)(3) nonprofit founded in 2019 by Seth Greenblott, along with co-founders Justin West, MD and Samantha MacMechan, to serve families affected by KCNT1-related epilepsy — an ultra-rare genetic disorder with fewer than 20 cases per million people, causing severe and often intractable seizures, severe developmental delay, and elevated mortality risk including SUDEP. The foundation is headquartered (mailing address) in Scottsdale, Arizona, operates with an all-volunteer Board of Directors and 1-10 employees, and serves a global community spanning the United States, Canada, the United Kingdom, Portugal, Germany, and Australia. There are no FDA-approved disease-modifying therapies for KCNT1-related epilepsy.

The foundation's core products are organized around three pillars: family support, research acceleration, and clinical trial readiness. Research infrastructure includes the KCNT1 International Registry (100+ enrolled patients with documented variants), a Digital Natural History Study conducted with Invitae/Ciitizen (50+ U.S. patients contributing medical records and genetic reports), and a biobank with biospecimen collection and hiPSC development through COMBINEDBrain and Van Andel Institute (since 2023). Family-facing products include the Family Contact List, Parent Ambassador Program, an annual Family and Professional Conference, multilingual educational resources (Portuguese, French, German, Spanish), and FDA Patient Listening Sessions (held April 22, 2024). Research funding is delivered through seed grants, the Penn Orphan Disease Center Million Dollar Bike Ride (raising ~$38K in 2024 and ~$39K in 2023, each unlocking ~$30K in matching), and a co-funded $100,000 Rare Epilepsy Partnership Award with CURE Epilepsy.

The foundation operates as a patient-driven, community-led organization. Revenue is generated entirely from charitable donations, fundraising events (golf tournaments, MDBR, Facebook/GoFundMe), corporate matching, eBay affiliate sales, conference sponsorships from biotech/pharma, and grants — most notably the multi-year Chan Zuckerberg Initiative Rare As One Network grant awarded in October 2024. GTM is community-led: families are reached via the website, email newsletters, Facebook (including private support groups), in-person conferences, and earned media (LA Times, Fox 32, ABC, ITV). Strategic partners span biotech (Actio Biosciences, Atalanta Therapeutics, Biogen, Praxis/UCB), academic researchers (UCL, UC Davis, CHOP), and rare disease infrastructure (NORD, CZI, COMBINEDBrain, Van Andel Institute, Penn ODC, CURE Epilepsy).

KCNT1 Epilepsy Foundation firmographics

Firmographics
Name
KCNT1 Epilepsy Foundation
Legal name
KCNT1 Slack Epilepsy Foundation
Website
https://kcnt1epilepsy.org
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
The KCNT1 Epilepsy Foundation is a Scottsdale-based 501(c)(3) nonprofit founded in 2019 that operates a patient registry, biobank, and digital natural history study to accelerate research and clinical trial readiness for the ultra-rare KCNT1-related epilepsy community worldwide.
Ownership category
akta.pro rank

KCNT1 Epilepsy Foundation industry classification

Industry
Product category
Rare Disease Patient Advocacy & Epilepsy Research Foundation
NAICS
Voluntary Health Organizations (813212)
SIC
Services-Social Services (8300)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAKAIAB
Epilepsy & Seizure Disorders
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAIAO
Neurogenetics & Rare Neurologic Diseases

Keywords

  • Rare disease advocacy
  • Epilepsy research foundation
  • Patient registry services
  • Family support services
  • Clinical trial readiness

Where KCNT1 Epilepsy Foundation is headquartered

Location

Headquarters

HQ city
Scottsdale
HQ country
United States
HQ region
North America

Offices1 record

Markets served

KCNT1 Epilepsy Foundation business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Charitable Donations: Individual donations from supporters via PayPal Giving Fund, credit card, check, Donor Advised Funds, IRA Required Minimum Distributions (RMDs/ QCDs), corporate matching, and eBay sales through affiliate programs.
  2. Fundraising Events: Revenue from events including Million Dollar Bike Ride, golf tournaments, Facebook fundraisers, and GoFundMe campaigns.
  3. Conference Sponsorships: Sponsorship revenue from pharmaceutical companies and industry partners for family and professional conferences.
  4. Mission-Aligned Financial Arrangements: The foundation may participate in revenue sharing, cost recovery, licensing, or other financial-return provisions through biobank partnerships, data partnerships, research collaborations, or potential spinout-related agreements.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

KCNT1 Epilepsy Foundation product offering

Product offering

Core offering

The KCNT1 Epilepsy Foundation is a 501(c)(3) nonprofit that supports families affected by KCNT1-related epilepsies and accelerates research toward disease-modifying treatments. It operates a KCNT1 International Registry (>100 patients), a U.S. Digital Natural History Study with Ciitizen (>50 patients), a biobank with iPSC biospecimens through COMBINEDBrain/Van Andel Institute, a Family Contact Network connecting parents globally, a Research Funding Program issuing seed and Million Dollar Bike Ride grants, and FDA Patient Listening Sessions representing community needs to regulators.

Product overview

The KCNT1 Epilepsy Foundation offers a comprehensive suite of patient-centered services organized around three pillars: family support, research acceleration, and community building. The core offerings include a Family Contact List and Network connecting affected families worldwide; a KCNT1 Registry and Biobank (in partnership with COMBINEDBrain and Van Andel Institute) collecting patient data and biospecimens; a Digital Natural History Study with Ciitizen; a Clinical Trial Hub preparing families for trial participation; and a Research Funding Program providing seed grants and partnering on research initiatives. The Foundation also organizes Family and Professional Conferences, facilitates FDA Patient Listening Sessions, and operates a Donation Platform with multiple giving mechanisms. All services work together to accelerate discovery of disease-modifying treatments for KCNT1-related epilepsy.

Differentiator

Problem solved

Functional benefit

Products and services

  • Family Contact List / Family Network A contact registry connecting families affected by KCNT1-related epilepsy. Parents and caregivers can register via online forms (available in English, Portuguese, French, German, and Spanish) to receive updates about educational events, research opportunities, and clinical trials, and to connect with other KCNT1 families globally.
  • KCNT1 International Registry and Biobank A detailed, secure, and re-contactable patient database with known KCNT1 mutation variants (over 100 persons enrolled) and a biobank collecting biospecimens for iPSC development and trio genome testing, operated in partnership with COMBINEDBrain and Van Andel Institute, with brain tissue from two donors available through NIH Neurobank.
  • Digital Natural History Study A U.S. digital natural history study operated in partnership with Ciitizen (Invitae) that uses patient medical records and genetic reports to characterize KCNT1-related epilepsy progression and accelerate rare disease drug development, covering more than 50 patients.
  • Clinical Trial Hub Information and resources about ongoing and upcoming clinical trials for KCNT1-related epilepsy, helping families understand trial opportunities, navigate informed consent (including ASO therapy education), and prepare for participation.
  • Research Funding Program Seed grants, targeted research priorities, and partnership programs funding high-impact KCNT1 research to accelerate therapeutic development, including Million Dollar Bike Ride grants (with Penn ODC matching up to $30,000) and co-funding partnerships with organizations such as CURE Epilepsy (e.g., $100,000 Rare Epilepsy Partnership Award).
  • Research Library A Zotero-hosted library containing scientific publications related to KCNT1/Slack Ion Channelopathy and epilepsy research, providing access to academic literature for researchers and clinicians.
  • Family and Professional Conferences Annual in-person and virtual conferences connecting KCNT1 families, clinicians, researchers, and industry partners, featuring educational presentations, clinical trial readiness guidance, networking opportunities, scientific updates, and ASO education sessions.
  • Parent Ambassador Program A network of parent ambassadors who connect affected families and spread awareness of KCNT1-related epilepsy in their regions and countries (e.g., Canada, UK, Portugal), supporting community building and education efforts.
  • FDA Patient Listening Sessions Facilitated sessions where KCNT1 patients, caregivers, and advocates share their experiences with the U.S. Food and Drug Administration to emphasize the urgent need for effective treatments, communicate caregiver perspectives on meaningful treatment outcomes and risk tolerance, and inform regulatory processes.

Quantifiable outcome

  • Over 100 persons with KCNT1 variants enrolled in registry
  • +4 more outcomes

Companies that use KCNT1 Epilepsy Foundation

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles3 records

KCNT1 Epilepsy Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

KCNT1 Epilepsy Foundation partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered minor and core.

  • Dee-P ConnectionsminorStrategic or Co-development Partner · 30 June 2026Partnership for educational session on ASO therapies and informed consent process for clinical research, featuring Dr. Olivia Kim-McManus and parent panel.
  • NORD (National Organization for Rare Disorders)coreStrategic or Co-development Partner · 15 May 2026Launch of Global KCNT1 Registry in partnership with NORD, expanding the foundation's patient registry capabilities internationally.
  • Actio BiosciencescoreStrategic or Co-development Partner · 18 February 2025Foundation co-founder Dr. Justin West engaged with Actio, whose KCNT1 program ABS-1230 is advancing into preclinical testing. Actio developing oral first-in-class small molecule inhibitor for KCNT1-related epilepsy.
  • Atalanta TherapeuticscoreStrategic or Co-development Partner · 31 January 2025Atalanta's ATL-201 announced as promising treatment using divalent small interfering RNA (siRNA) technology. Suppressed seizures in genetic mouse model. Advancing toward IND submission and Phase 1 clinical trial.
  • Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development Partner · 7 June 2024Conference collaboration hosting first in-person meeting with 14 families from multiple countries. CHOP provided optional clinic appointments and professional presentations on clinical trial readiness.
  • CURE EpilepsycoreStrategic or Co-development Partner · 20 May 2024Co-funding partnership for a $100,000 Rare Epilepsy Partnership Award, co-funding research grants to accelerate KCNT1 research priorities and double the foundation's research reach.
  • UC Davis - Jill Silverman Lab (Sarah Olguin)coreStrategic or Co-development Partner · 1 January 20242024 MDBR grant for characterizing seizures in new KCNT1 G288S mouse model to understand disease mechanisms and support preclinical testing.
  • Children's Hospital of Philadelphia - Dr. Jillian McKeecoreStrategic or Co-development Partner · 1 January 20242024 Seed Grant using electronic medical records and computational tools to analyze symptoms, medications, and genetic factors to inform clinical trial design.
  • Quiver BiosciencecoreStrategic or Co-development Partner · 1 January 20242024 co-funded grant with CURE Epilepsy for patient-derived iPSC neuronal models to study KCNT1 function and enable therapeutic screening.
  • NeuCytecoreStrategic or Co-development Partner · 1 January 20242024 Research Grant for high-throughput functional testing of KCNT1 variants to understand mutation-specific effects and evaluate therapeutic approaches.
  • COMBINEDBraincoreStrategic or Co-development Partner · 1 January 2023Biobank partnership for biospecimen collection beginning in 2023, with development of induced pluripotent stem cells (hiPSCs) for research purposes.
  • Van Andel InstitutecoreStrategic or Co-development Partner · 1 January 2023Partnership for biospecimen collection as part of the COMBINEDBrain biorepository initiative, supporting the foundation's biobank development.
  • University College London (Dr. Rajvinder Karda Lab)coreStrategic or Co-development Partner · 1 January 2023MDBR grant awarded for RNA editing treatment project. Collaboration with Dr. Karda, Dr. Chilcott, Dr. Keegan, Dr. Antonio, Dr. McTague, and Dr. Lignani on pioneering gene therapy research.
  • UCB and Praxis Precision MedicinesminorStrategic or Co-development Partner · 13 December 2022Strategic collaboration between UCB and Praxis based on Praxis' PRAX-020 program for discovery of small molecule therapeutics for KCNT1 related epilepsies.
  • BiogenminorStrategic or Co-development Partner · 1 August 2022Biogen announced KCNT1 ASO (antisense oligonucleotide) development. Dr. Viet Nguyen presented at foundation research roundtables on gene-based therapy pipeline.
  • Invitae CiitizencoreTechnology or Integration · 25 February 2021Partnership to launch a digital natural history study using Ciitizen's technology platform. The study collects and analyzes patient medical records and genetic reports for over 50 U.S. patients to accelerate rare disease drug development.
  • NIH NeurobankminorStrategic or Co-development Partner · 1 January 2019Brain tissue from two donors available through NIH Neurobank for KCNT1 research.
  • Penn Orphan Disease CentercoreStrategic or Co-development Partner · 1 January 2019Annual Million Dollar Bike Ride partnership. The ODC matches funds raised (up to $30,000) and distributes grants to researchers worldwide with no overhead. Raised nearly $38,000 in 2024 unlocking $30,000 match.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

KCNT1 Epilepsy Foundation competitors and assessment

Company assessment

Broad incumbents

  • CURE Epilepsy: Established nonprofit funding epilepsy research broadly, with co-funding partnership with KCNT1 Epilepsy Foundation on the $100K Rare Epilepsy Partnership Award. Highly comparable as a patient-driven funder in the epilepsy research space.
  • Epilepsy Foundation: Largest US epilepsy patient advocacy organization with broad research funding, family support, and FDA engagement programs. Comparable operating model but at much greater scale across all epilepsies, not just KCNT1.
  • Child Neurology Foundation: Broader patient/professional organization supporting families affected by pediatric neurologic conditions including rare genetic epilepsies. Comparable in family support and clinician engagement mission.

Direct peers

  • SLC6A1 Connect: Family-driven 501(c)(3) for ultra-rare genetic neurological disorder with patient registry, natural history study, research funding, and active biotech partnerships. Same playbook as KCNT1 Foundation.
  • STXBP1 Foundation: Parent-founded 501(c)(3) for ultra-rare genetic encephalopathy with registry, biobank, family conferences, research grants, and gene therapy partnerships. Near-identical operating model and scale to KCNT1 Foundation.
  • National Organization for Rare Disorders (NORD): Umbrella rare disease nonprofit that hosts patient registries and partners with disease-specific foundations; KCNT1 Epilepsy Foundation is actively partnering with NORD to launch its global registry. Directly comparable in registry infrastructure and grantmaking.
  • COMBINEDBrain: Nonprofit consortium advancing therapies for ultra-rare neurodevelopmental disorders, partnered with KCNT1 Foundation for biobank/biorepository since 2023. Directly comparable patient-data and biospecimen infrastructure model.
  • Dravet Syndrome Foundation: Disease-specific nonprofit for another severe genetic epilepsy with similar mission structure: patient registry, research grants, family conferences, biotech partnerships, and FDA engagement. Closest analog in scale and operating model.
  • SCN8A Union / Wishes for Elliott: Family-led nonprofit for SCN8A-related epilepsy, another ion channelopathy with analogous patient registry, family support, and biotech partnership approach to KCNT1.
  • PCDH19 Alliance: Small parent-founded nonprofit supporting research and families affected by PCDH19-related epilepsy, a similarly ultra-rare genetic seizure disorder. Comparable scale, mission, and community-led model.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

KCNT1 Epilepsy Foundation social profiles

Digital presence

KCNT1 Epilepsy Foundation compliance and trust

Trust signal

Compliance3 records

KCNT1 Epilepsy Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KCNT1 Epilepsy Foundation leadership team

Management profile

Number of profiles

Profiles5 records

KCNT1 Epilepsy Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KCNT1 Epilepsy Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KCNT1 Epilepsy Foundation

What does KCNT1 Epilepsy Foundation do?

The KCNT1 Epilepsy Foundation is a 501(c)(3) nonprofit that supports families affected by KCNT1-related epilepsies and accelerates research toward disease-modifying treatments. It operates a KCNT1 International Registry (>100 patients), a U.S. Digital Natural History Study with Ciitizen (>50 patients), a biobank with iPSC biospecimens through COMBINEDBrain/Van Andel Institute, a Family Contact Network connecting parents globally, a Research Funding Program issuing seed and Million Dollar Bike Ride grants, and FDA Patient Listening Sessions representing community needs to regulators.

Is KCNT1 Epilepsy Foundation a public or private company?

KCNT1 Epilepsy Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was KCNT1 Epilepsy Foundation founded?

KCNT1 Epilepsy Foundation was founded in 2019. It employs 11 to 50 people.

Where is KCNT1 Epilepsy Foundation based?

KCNT1 Epilepsy Foundation is headquartered in Scottsdale, United States, in the North America region.

How does KCNT1 Epilepsy Foundation make money?

Four revenue lines are on record. Charitable Donations are the primary driver. The others are fundraising Events, conference Sponsorships and mission-Aligned Financial Arrangements.

Who are KCNT1 Epilepsy Foundation's main competitors?

Broad incumbents on record are CURE Epilepsy, Epilepsy Foundation and Child Neurology Foundation. Direct peers are SLC6A1 Connect, STXBP1 Foundation, National Organization for Rare Disorders (NORD), COMBINEDBrain, Dravet Syndrome Foundation, SCN8A Union / Wishes for Elliott and PCDH19 Alliance.

Does KCNT1 Epilepsy Foundation have an API?

No public API is recorded for KCNT1 Epilepsy Foundation.

What industry is KCNT1 Epilepsy Foundation in?

KCNT1 Epilepsy Foundation's product category is Rare Disease Patient Advocacy & Epilepsy Research Foundation. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of HLAKAIAB, Epilepsy & Seizure Disorders. Its NAICS code is 813212 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireThe KCNT1 Epilepsy Foundation and NORD® Launch Global KCNT1 RegistryThe KCNT1 Epilepsy Foundation and NORD launched the KCNT1 International Registry on April 29, 2026, to collect data from individuals with KCNT1 gene variants. The registry aims to support drug development and improve care, with no cure currently available for KCNT1-related conditions.EIN PresswireKCNT1 Epilepsy Foundation Expands Board with Appointments of Meg Snowden, JD, and Sean Turbeville, PhDThe KCNT1 Epilepsy Foundation announced the appointment of Margaret (Meg) Snowden, JD, and Sean Turbeville, PhD, to its Board of Directors, bringing decades of combined expertise in biopharmaceutical intellectual property, rare disease research, and life sciences to the nonprofit. Snowden, a 35-year IP veteran with past roles at Impax Laboratories and Valentis, and Turbeville, a 25-year life sciences leader specializing in rare and ultra-rare diseases, will help guide the Foundation's strategy as KCNT1 epilepsy research enters the clinical trials and gene therapy era. The Foundation, which serves families in more than 60 countries, stated the appointments will strengthen its governance and global partnerships to accelerate treatments for the rare and often fatal neurodevelopmental disorder.PR NewswireLUNA LAUNCHES COMMUNITY DRIVEN INNOVATION™LunaPBC announced the launch of Community Driven Innovation (CDI), a participant-centered research methodology designed to deliver unbiased understanding of group priorities in weeks rather than years, improving upon traditional approaches like Delphi and design thinking. CDI has been applied to research projects by multiple patient advocacy organizations including KCNT1 Epilepsy Foundation, PXE International, and the Aicardi Goutières Syndrome Advocacy Association. The company will discuss the methodology's impact on patient community engagement at the American Public Health Association annual meeting in November 2022.